XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Revenue- Gilead Science Inc (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 7 Months Ended
Oct. 14, 2022
Jun. 30, 2024
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Jul. 31, 2022
Dec. 31, 2023
Sep. 30, 2023
Collaboration And Other Agreements [Line Items]                  
Revenues     $ 10,797 $ 13,136 $ 19,901 $ 37,632      
Deferred revenue, current   $ 23,818 23,818   23,818     $ 21,651  
Deferred revenue, net of current portion   55,503 55,503   55,503     59,243  
Gilead | 2022 Gilead Collaboration And License Agreement                  
Collaboration And Other Agreements [Line Items]                  
Non-refundable upfront payment             $ 60,000    
Revenues     200 $ 200 500 $ 600      
Deferred revenue   57,800 57,800   57,800     58,300  
Deferred revenue, current   2,300 2,300   2,300     2,200  
Deferred revenue, net of current portion   55,500 55,500   55,500     56,100  
Potential target nomination, option fees and milestone payments $ 1,700,000                
Gilead | Gilead First Research Program                  
Collaboration And Other Agreements [Line Items]                  
Revenues   3,300 1,300   2,000        
Deferred revenue   16,200 16,200   16,200     14,900  
Deferred revenue, current   $ 16,200 $ 16,200   $ 16,200     11,800  
Deferred revenue, net of current portion               $ 3,100  
Revenue, remaining performance obligation, amount                 $ 15,700
Potential option fees                 $ 10,000